Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Hematologic Neoplasms|Bone Marrow Neoplasms|Non-Hodgkin's Lymphoma
DRUG: Darinaparsin
Response Rate, 6 months
toxicities, 6 months
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.